A cost-effectiveness analysis of axillary node dissection in postmenopausal women with estrogen receptor-positive breast cancer and clinically negative axillary nodes

Keyphrases

• Postmenopausal Women 100%
• Estrogen Receptor-positive Breast Cancer 100%
• Cost-effectiveness Analysis 100%
• Axillary Nodes 100%
• Axillary Lymph Node Dissection 100%
• Tumor 27%
• Quality-adjusted Life Years 27%
• Chemotherapy 18%
• Estrogen Receptor-positive 18%
• Incremental Cost 18%
• Positive Lymph Nodes 18%
• Non-culprit Lesion 18%
• Palpable Tumor 18%
• Older Women 9%
• Cost-effectiveness 9%
• Patient Preference 9%
• Young Women 9%
• Recurrence Risk 9%
• Cost-benefit 9%
• Low Risk 9%
• Tumor Size 9%
• Prognostic Factors 9%
• Markov Model 9%
• Treatment Costs 9%
• Improved Survival 9%
• Nodal Metastasis 9%
• Cost-effectiveness Ratio 9%
• Reasonable Cost 9%
• Axilla 9%
• Patient Subgroups 9%
• Watchful Waiting 9%
• Quality-adjusted Survival 9%
• Preoperative Chemotherapy 9%
• Survival Cost 9%
• Palpability 9%

Medicine and Dentistry

• Cost-Effectiveness Analysis 100%
• Postmenopause 100%
• Retroperitoneal Lymph Node Dissection 100%
• Axillary Lymph Node 100%
• Estrogen Receptor Positive Breast Cancer 100%
• Neoplasm 60%
• Health Care Cost 40%
• Quality Adjusted Life Year 40%
• Chemotherapy 30%
• Lymph Node 20%
• Estrogen Receptor 20%
• Prognostic Factor 10%
• Recurrence Risk 10%
• Patient Preference 10%
• Axilla 10%
• Watchful Waiting 10%
• Nodal Metastasis 10%